Xeljanz Dosing and Administration for Rheumatoid Arthritis

Dosing Recommendations

• The FDA-approved starting dose for rheumatoid arthritis is 5 mg twice daily, taken orally, which has been extensively studied across multiple Phase 3 trials and demonstrates significant efficacy in reducing signs and symptoms of RA while maintaining an acceptable safety profile 1, 2, 3, 4
• An extended-release formulation of 11 mg once daily is an alternative option 5
• The 10 mg twice daily dose is specifically not recommended for RA treatment due to increased thromboembolic risk 6, 7

Clinical Context

• The 5 mg twice daily dose has demonstrated ACR20 response rates of 51.5-73.1% across multiple trials 1, 4
• Significant improvements in HAQ-DI scores (mean changes of -0.40 to -0.44) have been observed 1, 4
• Remission rates (DAS28-ESR <2.6) of 5-10% at 3 months and 7.2-8.5% at 6 months have been reported 4

Administration Guidelines

• Xeljanz can be used as monotherapy or in combination with methotrexate or other conventional DMARDs 1, 4
• It should not be combined with potent immunosuppressants (azathioprine, cyclosporine) or biologics 8

Dose Adjustments Required

• The dose should be reduced to 5 mg once daily in patients with moderate to severe renal impairment (CrCl 30-60 mL/min), moderate to severe hepatic impairment (Child-Pugh B or C), or those taking concomitant strong CYP3A4 inhibitors (e.g., ketoconazole) 5, 8
• A dose reduction to 5 mg once daily is also recommended for patients taking concomitant moderate CYP3A4 inhibitors plus potent CYP2C19 inhibitors (e.g., fluconazole) 8

Critical Safety Considerations

• It is essential to screen for latent tuberculosis before initiating therapy 6
• Consideration should be given to herpes zoster vaccination before starting Xeljanz, especially in patients >50-70 years 6, 9
• Xeljanz should be avoided in patients with active serious infections 5
• Use caution in elderly patients (≥65 years) with cardiovascular risk factors due to increased infection and thromboembolic risk 5, 6

Efficacy Timeline

• Patients can expect an initial response typically seen within 2-4 weeks 1, 4, 6
• Maximal benefit is usually achieved by 3-6 months 2, 6

Tofacitinib Therapy for Rheumatoid Arthritis

Positioning in Treatment Algorithm

• The European League Against Rheumatism (EULAR) recommends tofacitinib after failure of at least one biologic DMARD, due to safety concerns, with a treatment sequence starting with conventional synthetic DMARDs, followed by biologic DMARDs, and then tofacitinib 10, 11, 12

Dosing and Administration

• The American College of Rheumatology does not explicitly recommend tofacitinib dosing, however, the FDA-approved dose is 5 mg twice daily orally, and the European Medicines Agency approves its use with methotrexate for psoriatic arthritis, with a recommended dose reduction to 5 mg once daily in patients with moderate to severe renal or hepatic impairment 10, 11

Critical Safety Considerations

• The use of tofacitinib is associated with an increased risk of thromboembolic events, particularly deep vein thrombosis, and should be used with caution in elderly patients with cardiovascular risk factors, as recommended by the European League Against Rheumatism (EULAR) 10, 11
• EULAR also recommends regular monitoring of complete blood counts, lipid panels, liver function tests, and serum creatinine to minimize the risk of adverse events 12

Tofacitinib Safety and Monitoring in Rheumatoid Arthritis

High‑Risk Patient Identification

• The European Medicines Agency advises that tofacitinib should be reserved for patients ≥ 65 years of age, current or long‑term former smokers, those with a history of cardiovascular disease, increased malignancy risk, or elevated venous thromboembolism (VTE) risk, only when no suitable alternative therapy exists【13】.
• Cardiovascular risk assessment should include age ≥ 65 years, smoking history, prior cardiovascular disease, and history of malignancy【13】【14】.
• VTE risk assessment should consider heart failure, active malignancy, recent surgery, inherited coagulation disorders, and use of combined hormonal contraception or hormone‑replacement therapy【13】【14】.

Vaccination Recommendations

• Herpes‑zoster vaccination is recommended before initiating or continuing tofacitinib in patients ≥ 50–70 years who have not previously received the vaccine【13】.
• Live vaccines should be avoided while on tofacitinib; ensure zoster vaccination is completed beforehand if indicated【15】.

Evidence of Safety Signals (ORAL Surveillance)

Strength of evidence: Phase 3 randomized controlled trial (ORAL Surveillance) with robust safety endpoints.

Treatment Recommendations for High‑Risk Patients

• For patients meeting any high‑risk criteria (age ≥ 65, smoking, cardiovascular disease, malignancy risk, VTE risk), switch to an alternative biologic DMARD (e.g., TNF inhibitor, abatacept, tocilizumab, or rituximab) rather than continuing tofacitinib【13】【16】.
• The 10 mg twice‑daily dose of tofacitinib should not be used because of the documented increase in thromboembolic events【13】.

Disease Activity Monitoring

• Assess disease activity every 1–3 months using validated instruments such as DAS28 or CDAI【16】.
• Re‑evaluate treatment targets at 6 months to confirm achievement of remission or low disease activity【16】.

Ongoing Safety Monitoring

• Vigilance for new cardiovascular symptoms or signs of VTE is essential, given the established increased risk associated with tofacitinib【13】【14】.